JPRN-UMIN000010739已完成未知
Phase II trial of amrubicin treatment as palliative-intended chemotherapy for previously treated malignant pleural mesothelioma - Phase II study of amrubicin for previously treated malignant pleural mesothelioma
Tokyo Metropolitan Cancer and Infection diseases Center Komagome Hospital0 个研究点目标入组 6 人开始时间: 2013年5月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) The age of less than 70 years-old 2) Previously treated with chemotherapy 3) With uncontrolled brain metastasis 4) With clinically active infection 5) With severe complication (cardiac diseases, interstitial pneumonia, uncontrolled hypertension or diabetes) 6) With uncontrolled pleural effusion 7) With active other organ cancer 8) With the history of severe drug allergy 9) With the history of hypersensivity for paclitaxel, albumin-containing agents 10) With the history of hypersensitivity for platinum agents 11) With uncontrolled digestive ulcer 12) Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
已完成
2 期
Phase II study of amrubicin monotherapy for treating elderly and poor-risk patients with small-cell lung cancer.small cell lung cancerJPRN-UMIN000011055Kitasato University School of Medicine Department of Respiratory Medicine34
已完成
2 期
A phase II study of amrubicin for previously treated small cell lung cancerFor patients with recurrent small cell lung cancerJPRN-UMIN000001752Gunma University Hospital35
已完成
2 期
Phase II study of amrubicin for previously treated advanced non-small cell lung cancerRecurrent non-small cell lung cancerJPRN-UMIN000001751Gunma University Hospital35
已完成
2 期
A Phase 2 Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First Line Platinum-based Chemotherapyextensive Small Cell Lung Cancer10038716lung cancerNL-OMON30587PharmionCorporation6
已完成
2 期
Phase ll trial of Amrubicin in Patients with Priviously Treated Advanced Non-Small Cell Lung Cancerung Squamous Cell CarcinomaJPRN-UMIN000004832First Department of Surgery, Hamamatsu University School of Medicine35